Compare Lemonade Inc (LMND) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lemonade Inc vs Twist Bioscience Corp — how do they compare? Lemonade Inc trades at $53 (market cap $4.00B), while Twist Bioscience Corp trades at $125.75 (market cap $7.86B). The key difference: Twist Bioscience Corp is the larger of the two by market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Lemonade Inc nearer its low. Which is the better fit depends on your goals.
| LMND | TWST | |
|---|---|---|
Market Cap | $4.00B | $7.86B |
Sector | Financials | Health |
52-Week High | $96.57 | $125.21 |
52-Week Low | $47.38 | $24.16 |
Enterprise Value | $3.86B | $7.79B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lemonade (LMND) trades at $52.98, up 0.21% on the day, with a bearish technical signal from moving averages but recent earnings beats. Revenue growth is strong, reaching $737.9M in 2025, yet the company remains unprofitable with a net income margin of -14.19%. Analyst sentiment is mixed with a consensus price target of $58.00. Recent news highlights a CFO transition and expansion into new states.
The outlook hinges on achieving profitability, with guidance for positive adjusted EBITDA in Q4 2026. Investment opportunity lies in continued premium growth and margin improvement, but risks include persistent losses, competitive pressures, and execution challenges. The stock presents a high-risk, high-reward profile for growth-oriented investors.
Twist Bioscience (TWST) trades at $125.16, up 1.66% today, with a bullish technical signal from moving averages but overbought RSI readings. Revenue growth is strong, with Q3 2026 revenue up 23% year-over-year to $118.4 million, though the company remains unprofitable with a net income margin of -31.66%. Recent news highlights a $300 million public offering and expansion in AI-driven drug discovery, fueling investor optimism.
The outlook is mixed: robust revenue growth and analyst buy ratings (78.57%) support upside, but persistent losses, high valuations (P/S of 17.73), and cash flow deficits pose risks. Investors should weigh the potential for EBITDA breakeven by fiscal 2027 against execution challenges in a competitive biotech landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Lemonade Inc
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes.
Read more on LMND →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
